A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours by Herpen, C.M.L. (Carla) et al.
A Phase Ib dose-escalation study to evaluate safety and
tolerability of the addition of the aminopeptidase inhibitor
tosedostat (CHR-2797) to paclitaxel in patients with
advanced solid tumours
CML van Herpen*,1, FALM Eskens2, M de Jonge2, I Desar1, L Hooftman3, EA Bone3, JNH Timmer-Bonte1
and J Verweij2
1Department of Medical Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands;
2Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands; 3Chroma Therapeutics Ltd., 93 Milton Park,
Abingdon OX14 4RY, UK
BACKGROUND: This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT),
pharmacokinetics (PK) and clinical antitumour activity of tosedostat (CHR-2797), an orally bioavailable aminopeptidase inhibitor, in
combination with paclitaxel.
METHODS: A total of 22 patients received paclitaxel (135–175mgm2) intravenously, administered once every three weeks for up to
six cycles, with oral tosedostat (90–240mg) daily.
RESULTS: One DLT (grade 3 dyspnoea) was observed in one patient with tosedostat 180mg combined with paclitaxel 175mgm2.
A high number of paclitaxel infusion reactions was noted during the second administration (59%) and this prompted interruption of
tosedostat dosing for 5 days around every second and subsequent paclitaxel infusion. No formal MTD was determined because of
the high frequency of paclitaxel infusion reactions that may have been influenced by tosedostat. Most frequently observed
drug-related adverse events were alopecia, fatigue (95% each), peripheral sensory neuropathy (59%), paclitaxel hypersensitivity (59%)
and rash (55%). One patient died because of eosinophilic myocarditis, possibly related to study medication. There was no PK interaction
between tosedostat and paclitaxel. In all, 3 patients had a partial response and 12 patients had stable disease lasting 43 months.
CONCLUSION: The combination of tosedostat with paclitaxel was well tolerated except for the high incidence of paclitaxel-related infusion
reactions.
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Tosedostat (CHR-2797) is a novel metalloenzyme inhibitor that is
converted intracellularly into a pharmacologically active meta-
bolite CHR-79888. Being a poorly membrane-permeant acid,
intracellular accumulation of CHR-79888 is excellent. Tosedostat
is both antiproliferative and proapoptotic, and has demonstrated
antiangiogenic effects. Both in vitro and in vivo experiments have
shown selectivity for transformed over nontransformed cells
(Krige et al, 2008). CHR-79888 is a potent inhibitor of various
intracellular aminopeptidases, a number of which are over-
expressed in certain human tumour types. Aminopeptidases
catalyse the sequential removal of amino acids from the amino-
terminus of peptide/protein substrates, thereby regulating the
function of biologically active peptides, trimming antigens for
MHC class 1 presentation and modulating protein recycling (Saric
et al, 2004).
Although the mechanism of the antiproliferative effect of
aminopeptidase inhibition remains to be fully elucidated, gene
expression analysis of the human promyelocytic leukaemia cell
line HL-60, exposed to tosedostat revealed a transcriptional
response to the drug indicative of amino acid depletion, a
so-called amino acid deprivation response (AADR; Krige et al,
2008). Tosedostat also inhibited phosphorylation of mTOR
substrates and reduced protein synthesis in these cells, indicating
amino acid depletion (Krige et al, 2008). One of the consequences
of AADR is upregulation of proapoptotic protein markers such as
CHOP (C/EBP homologous protein) and Noxa. Taking these data
together suggests that tosedostat depletes sensitive tumour cells of
amino acids by blocking protein recycling and thereby generates
an antiproliferative effect (Figure 1). Tosedostat synergises with a
wide range of chemotherapeutic agents in inducing antiprolifera-
tive effects in a wide range of cancer cell lines in vitro (Jenkins
et al, 2007; Moore et al, 2009).
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Here, we present results of a Phase Ib trial (EudraCT number
2006–002498–35) designed to determine maximum tolerated dose
(MTD), dose-limiting toxicities (DLTs), pharmacokinetics (PK)
and preliminary activity of the combination of continuous (once)
daily tosedostat dosing, and 3-weekly paclitaxel infusions.
PATIENTS AND METHODS
Patient eligibility
Eligible patients were aged X18 years, and had histologically or
cytologically confirmed advanced solid malignancies, refractory to
conventional treatment. Patients were also required to have life
expectancy X12 weeks, Eastern Cooperative Oncology Group
(ECOG) performance status X2, adequate haematopoietic (abso-
lute neutrophil count X1.5 109 l1; platelets X100 109 l1),
hepatic (bilirubin p1.5 upper normal limit (ULN), aspartate
transaminase/alanine transaminase p2.5 1C ULN) and renal
(creatinine X1.5 ULN) function. Patients with previous anti-
cancer therapy within 4 weeks of study entry (6 weeks for
mitomycin and nitrosureas), known brain tumours or brain
metastases and patients who failed to recover from acute adverse
effects of previous therapies or who had received more than four
previous chemotherapy regimens were excluded. The local ethics
committees at both participating centres approved the study
protocol and written informed consent was obtained from all
patients before any study-related procedures.
Study design and dose-escalation schedule
Cohorts of three to six patients were administered intravenous
(i.v.) paclitaxel over 3 h every 21 days in combination with
escalating oral doses of tosedostat.
Patients received up to six cycles of paclitaxel. Premedication
consisted of dexamethasone, clemastine and a histamine
H2-receptor antagonist and was administered i.v. 30–60min
before paclitaxel. Tosedostat capsules (10, 20 and 40mg) were
taken after food at the same time every day from day 2 onwards,
with the exception of day 22, when blood was drawn for a second
PK profile and tosedostat was withheld until 1 h after the end of the
paclitaxel infusion.
The first cohort of three patients received a low, but registered
and effective dose of paclitaxel (135mgm2). The starting dose of
CHR-2797 was 90mg daily, below the MTD. Other planned cohorts
in this study were: cohort 2: paclitaxel 175mgm2 and tosedostat
90mg; cohort 3: paclitaxel 175mgm2 and tosedostat 130mg;
cohort 4: paclitaxel 175mgm2 and tosedostat 180mg; cohort 5:
paclitaxel 175mgm2 and tosedostat 240mg; cohort 6: paclitaxel
200mgm2 and tosedostat 240mg. After cohort 4, an amendment
was implemented allowing for dose interruption of tosedostat,
which resulted in the following cohorts: cohort 5: paclitaxel
175mgm2 and tosedostat 180mg from day 2–17 of each cycle;
cohort 6: paclitaxel 175mgm2 and tosedostat 240mg from day
2–17 of each cycle.
Patients remained on therapy for as long as the investigator felt
that it was in their best interest and while there was no evidence of
progressive disease (PD) or unacceptable toxicity. Following
completion of paclitaxel therapy, patients could continue with
single agent tosedostat until evidence of PD or unacceptable toxicity.
Definition of MTD and DLT
Toxicity was evaluated according to common toxicity criteria for
adverse events (CTCAEv3.0). The MTD was defined as the dose
level(s) at which at least two out of six patients developed DLT. This
was defined as any of the following events possibly or probably
related to the paclitaxel/tosedostat combination and which occurred
during the first 21 days of treatment: grade 4 neutropenia lasting
X7 days or neutropenic fever/sepsis; grade 4 thrombocytopenia;
any drug-related, nonhaematological grade 3–4 toxicity with the
exceptions of fatigue and inadequately treated nausea and vomiting;
a delay in retreatment with paclitaxel of 47 days.
Patient evaluation and follow-up
Toxicity assessment, haematology and clinical biochemistry were
performed at baseline and weekly during the study. Physical and
ECOG performance status were recorded at baseline and before the
next cycle.
Response was evaluated according to Response Evaluation
Criteria in Solid Tumors (Therasse et al, 2000) after every second
cycle.
PK assessments
Pharmacokinetic samples were taken on days 1, 21 and 22, with a
24 h sample taken the following day, for determination of plasma
PK profiles of paclitaxel, tosedostat and CHR-79888. Subsequent to
dose interruptions permitted by amendment 2, it was no longer
meaningful to obtain full PK profiles, so sampling in cohorts 5 and
6 was reduced to one sample, taken before paclitaxel infusion on
day 22, for the determination of trough concentrations of
tosedostat and CHR-79888 in plasma. Plasma concentrations of
tosedostat, CHR-79888 and paclitaxel were measured using
validated LC-MS/MS bioanalytical methods.
The effect of tosedostat coadministration on the PK of paclitaxel
was evaluated by comparing PK parameters from the infusion of
day 1 with those of day 22. The effect of paclitaxel on the PK of
tosedostat and CHR-79888 was evaluated by comparing PK
parameters of day 21 with those of day 22 (the day of second
paclitaxel infusion). On day 21, samples were taken until 8 h post-
dose; the day 22 predose sample was used as the 24 h sample of day
21. Samples were taken until 24 h after the day 22 dose of
tosedostat. Peak plasma concentrations (Cmax), overall drug
exposure (AUC), and terminal plasma half-life (t1
2
) were calculated
using noncompartmental methods using WinNonlin Professional
software (version 4.1, Pharsight Corporation, St Louis, MO, USA).
Pharmacokinetics analysis, with reference to possible interactions,
was descriptive.
RESULTS
General trial conduct
This study was conducted at two academic cancer centres between
August 2006 and November 2007. In total, 22 patients were
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Figure 1 Mechanism of action of tosedostat. Tosedostat inhibits
aminopeptidase activity, which results in the depletion of cellular amino
acid pools selectively in tumour cells. This disrupts the turnover of cell cycle
intermediates in such a way that it impacts cancer cell survival or
proliferation.
Phase I trial of tosedostat (CHR-2797) and paclitaxel
CML van Herpen et al
1363
British Journal of Cancer (2010) 103(9), 1362 – 1368& 2010 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
enrolled. Patient characteristics are summarised in Table 1. One
patient was withdrawn after 7 days of treatment because of early
PD and was replaced; consequently, 21 patients were evaluable for
efficacy analyses, all of whom received at least two treatment
cycles. Six patients received just two cycles, one patient received
three cycles, five patients received four cycles, two patients
received five cycles and seven patients received six cycles. There
was no apparent correlation between number of cycles and dose
levels. Seven continued on tosedostat monotherapy: six patients
had completed six cycles of paclitaxel therapy and in one patient
paclitaxel was stopped after two infusions due to sensory
neuropathy.
DLTs and MTD
One patient with urethral cancer treated in cohort 5 (175mgm2
paclitaxel, 180mg tosedostat) experienced DLT: CTC grade 3
dyspnoea, with grade 2 fever and persistent grade 3 urinary tract
infection. In this patient, tosedostat was reduced to 130mg and
subsequently this cohort was expanded with three additional
patients, none of whom developed DLT.
There were no further DLTs in this trial. The three patients in
cohort 6 (175mgm2 paclitaxel, 240mg tosedostat) completed the
dose-escalation phase without any grade 3/4 toxicity. Nevertheless,
the trial steering committee decided to terminate the study. Formal
MTD was never reached in this trial, but in cohorts 3–6 paclitaxel
infusion reactions occurred in 73% of patients, despite routine
premedication.
Overall safety and tolerability
Adverse events (AEs) and serious adverse events (SAEs). All
patients experienced one or more AEs. The majority of these AEs
were disease-related and/or known side effects of paclitaxel and
were less often considered tosedostat-related by the investigators.
Table 2 summarises AEs occurring with a frequency of 420% or
gradeX3 in cycle 1 and in all cycles. The most frequently reported
AEs were alopecia (95%), fatigue (95%), peripheral sensory
neuropathy (59%), rash (55%) and drug hypersensitivity reaction
(HSR; 50%), which with interruptions of the paclitaxel infusion
and individually reported symptoms, contributed to an overall
59% incidence of infusion reactions.
A total of 19 SAEs were reported in 12 patients. In six patients
SAEs were considered paclitaxel and/or tosedostat-related. These
were decreased fluid intake (n¼ 1), allergic reaction (n¼ 1),
dyspnoea (n¼ 1), eosinophilic myocarditis (n¼ 1) and renal
insufficiency (n¼ 2). In all, 13 SAEs were considered disease-
related.
One patient (in Cohort 5) died 6 days after his third paclitaxel
infusion and 2 days after his last dose of tosedostat. He had been a
professional body builder for many years and his lifestyle included
a diet of up to 30 eggs per day in preparation for competitions and
the intermittent use of anabolic steroids (this was confirmed after
his death by relatives). An initial diagnosis of chondrosarcoma was
made in 2005. His medical history included hypertension, chronic
obstructive pulmonary disease and atypical retrosternal chest pain
(for several years), thought to be related to a hiatus hernia. His
pretreatment ECG had shown marked ST-T wave abnormalities
with signs of a possible old myocardial infarction (MI). After
4 days of his third paclitaxel infusion, he was admitted to hospital
as an emergency with an exacerbation of chest pain suggestive of
MI. Tosedostat was discontinued. After 2 days, he died from
cardiac failure with ventricular fibrillation and electromechanical
dissociation. A post-mortem examination revealed a dilated
concentric cardiomyopathy with hypertrophy of both ventricles
(weight of heart 530 g, compared withB350 g for a normal heart),
probably of chronic nature. An expert cardiac pathologist reviewed
slides of the myocardial tissue. Dense interstitial lymphocytic and
eosinophilic infiltrates throughout the ventricles were observed.
Other findings were a concomitant eosinophilic infiltrate in the
liver and signs of incomplete suppression of peripheral eosino-
phils, despite an apparent systemic stress response. Consequently,
the cause of death was eosinophilic myocarditis, considered
possibly related to paclitaxel, tosedostat or other medications.
One patient in cohort 5 discontinued paclitaxel after two cycles
following development of grade 3 sensory neuropathy. This patient
had a history of diabetes mellitus and metastatic colorectal cancer,
for which he had received previous systemic treatment including
oxaliplatin, capecitabine, bevacizumab, cetuximab and irinotecan.
During the first cycle he developed sensory neuropathy grade 1,
which increased to grade 3 after the second cycle. Neuropathy was
considered possibly related to tosedostat and definitely related to
paclitaxel. The patient continued with tosedostat monotherapy for
7 weeks until PD. The neuropathy did not resolve. Neuropathy led
to delay in dosing or dose reduction of paclitaxel in four other
patients and tosedostat dose interruption in one patient.
Paclitaxel infusion reactions. Infusion-related HSRs (grade 1,
three patients; grade 2, one patient; grade 3, seven patients) or
infusion interruptions (two patients, symptoms consistent with
such reactions) were reported in 59% of patients during second
and/or subsequent paclitaxel administrations. They are sum-
marised per dose level in Table 3. Before cohort 3, the paclitaxel
infusion schedule was amended to accommodate PK sampling
alongside the infusion interruption and additional premedication
required to manage these reactions. Before cohort 5, the regimen
was further modified by interrupting tosedostat dosing from
4 days before to 1 day after each paclitaxel infusion. This
did reduce incidence and severity of HSRs to some extent in
cohort 5, but in cohort 6 all patients experienced HSRs at their
second paclitaxel administration. All HSRs could be controlled
medically.
Laboratory parameters. For the main haematology parameters,
except for APTT, median values dropped after the first and
subsequent paclitaxel infusions, reaching a nadir on day 8
Table 1 Patient characteristics (n¼ 22)
Age, median (range; years) 59 (34–72)
Male/female 17/5
Performance score
0 12
1 8
2 2
Tumour type
Sarcoma 4
Bladder cancer 3
Gastric cancer 3
Colorectal cancer 2
NSCLC 2
Miscellaneous 8
Previous treatment
Systemic treatment (alone or in combination) 19
Chemotherapy 19
K 1 regimen 11
K 2 regimens 6
K 3 and 4 regimens 2
Docetaxel 2
Tyrosine kinase inhibitors 4
Hormonal treatment 1
Surgery (alone or in combination) 17
Radiotherapy (with other treatments) 10
Abbreviation: NSCLC¼ non-small-cell lung cancer.
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Table 2 Adverse events occurring in more than 20% of patients or any grade 3–5 during the first 21 days and during all cycles of treatment, worst grade
per person and regardless of relationship
Incidence of AEs during first 21 days,
worst grade per patient regardless of relation
Incidence of AEs during all cycles,
worst grade per patient regardless of relation
CTCAE grade
No. of patients
with events CTCAE grade
No. of patients
with events
Adverse event 1 2 3 4 5 n % 1 2 3 4 5 n %
Blood and lymphatic system disorders
Anaemia 1 1 0 0 0 2 9 1 3 1 0 0 5 23
Leukopenia 0 2 2 0 0 4 18 0 1 3 0 0 4 18
Neutropenia 0 1 2 3 0 6 27 0 0 2 4 0 6 27
Cardiac disorders
Eosinophilic myocarditis 0 0 0 0 0 0 0 0 0 0 0 1 1 5
Gastrointestinal disorders
Constipation 3 1 0 0 0 4 18 3 3 0 0 0 6 27
Diarrhoea 2 0 0 0 0 2 9 5 3 0 0 0 8 36
Gastric dilatation 0 0 1 0 0 1 5 0 0 1 0 0 1 5
Nausea 4 1 0 0 0 5 23 9 1 0 0 0 10 45
Vomiting 3 1 0 0 0 4 18 3 2 0 0 0 5 23
General disorders and administration site conditions
Fatigue 7 2 1 0 0 10 45 5 10 6 0 0 21 95
General physical health
deterioration
0 0 0 0 0 0 0 0 0 1 0 0 1 5
Malaise 0 1 0 0 1 5 1 1 1 0 0 3 14
Mucosal inflammation 2 1 0 0 0 3 14 4 1 0 0 0 5 23
Oedema 3 0 0 0 0 3 14 4 0 1 0 0 5 23
Oedema peripheral 4 1 0 0 0 5 23 6 2 0 0 0 8 36
Pyrexia 1 1 0 0 0 2 9 4 2 0 0 0 6 27
Immune system disorders
Drug hypersensitivity 0 0 0 0 0 0 0 3 1 7 0 0 11 50
Infections and infestations
Bronchitis 0 0 0 0 0 0 0 0 0 1 0 0 1 5
Cystitis 0 0 0 0 0 0 0 0 1 1 0 0 2 9
Nasopharyngitis 2 0 0 0 0 2 9 6 0 0 0 0 6 27
Urinary tract infection 0 0 1 0 0 1 5 0 1 1 0 0 2 9
Investigations
Alanine aminotransferase
increased
1 2 0 0 0 3 14 1 1 1 0 0 3 14
Blood bilirubin 0 0 0 0 0 0 0 0 0 1 0 0 1 5
g-glutamyltransferase increased 0 0 1 0 0 1 5 0 1 1 0 0 2 9
Metabolism and nutrition disorders
Anorexia 4 0 0 0 0 4 18 6 2 2 0 0 10 45
Dehydration 0 0 1 0 0 1 5 0 1 1 0 0 2 9
Diabetes mellitus 0 0 1 0 0 1 5 0 0 1 0 0 1 5
Hypercalcaemia 0 0 0 0 0 0 0 0 0 1 0 0 1 5
Hyperglycaemia 0 0 2 0 0 2 9 0 1 2 0 0 3 14
Musculoskeletal and connective tissue disorders
Arthralgia 5 0 0 0 0 5 23 5 0 0 0 0 5 23
Back pain 2 0 0 0 0 2 9 3 2 0 0 0 5 23
Myalgia 7 1 1 0 0 9 41 8 1 1 0 0 10 45
Neoplasms benign, malignant and unspecified (including cysts and polyps) 14
Tumour pain 0 0 1 0 0 1 5 0 1 2 0 0 3 14
Nervous system disorders 95
Dizziness 4 1 0 0 0 5 23 8 1 1 0 0 10 45
Peripheral sensory neuropathy 4 3 0 0 0 7 32 6 4 3 0 0 13 59
Spinal cord compression 0 0 0 0 0 0 0 0 0 1 0 0 1 5
Renal and urinary disorders 23
Pollakiuria 0 0 0 0 0 0 0 0 0 1 0 0 1 5
Respiratory, thoracic and mediastinal disorders 73
Cough 5 0 0 0 0 5 23 8 1 0 0 0 9 41
Dyspnoea 0 0 1 0 0 1 5 6 1 3 0 0 10 45
Pulmonary embolism 0 0 0 0 0 0 0 0 0 1 0 0 1 5
Skin and subcutaneous tissue disorders 100
Alopecia 7 8 0 0 0 15 68 1 20 0 0 0 21 95
Dry skin 0 0 1 0 0 1 5 3 0 1 0 0 4 18
Erythema 0 0 0 0 0 0 0 1 0 1 0 0 2 9
Hyperhidrosis 1 0 0 0 0 1 5 2 0 1 0 0 3 14
Pruritus 3 0 1 0 0 4 18 5 0 1 0 0 6 27
Rash 3 1 1 0 0 5 23 9 1 2 0 0 12 55
Abbreviations: AEs¼ adverse events; CTCAE¼ common toxicity criteria for adverse events.
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(platelets) or day 15 (haemoglobin, WBC, neutrophils and
lymphocytes) of each cycle. There was recovery to baseline value
(lymphocytes) or below baseline (other parameters) on day 21. In
subsequent cycles, WBC and neutrophil counts also tended to
recover to baseline values, whereas lymphocyte counts showed
a rebound increase to above baseline values by day 21 of cycles 4
and 5. Median platelet count and haemoglobin values did not
recover to baseline values during any of the cycles. Other
differential counts were recorded, but no changes of interest were
observed.
PK
The overall exposure to tosedostat and CHR-79888 increased in a
dose proportional manner.
Effect of coadministration of paclitaxel on PK of tosedostat and
CHR-79888. The effect of coadministration of paclitaxel on PK of
tosedostat and CHR-79888 was evaluated by comparing PK
parameters of days 21 and 22. Overall exposure to tosedostat
was unaffected by paclitaxel administration. However, a tendency
for a decreased Cmax and an increased tmax and t12 was observed,
suggesting that coadministration of paclitaxel affected the shape of
the tosedostat PK profile, but not the overall exposure. There was
no significant effect of paclitaxel on Cmax, AUC0t, tmax and
t1
2
values for CHR-79888 (Table 4).
Effect of coadministration of tosedostat on the PK of paclitaxel.
The effect of tosedostat on PK of paclitaxel was evaluated by
comparing PK parameters of paclitaxel of days 1 and 22. The PK
profiles were essentially overlapping (data not shown).
Antitumour activity
Partial responses (PR) were observed in 3 patients with malignant
melanoma, squamous cell non-small-cell lung cancer and
squamous-cell carcinoma of the oesophagus (14%; all confirmed
after X4 weeks) and stable disease was observed in 12 patients
(57%). The three PRs occurred at various dose levels and response
durations were 7.2, 7.1 and 1.5 months, respectively. Median (95%
CI) duration of s.d. was 5.6 (3–6.5) months.
DISCUSSION
The development of drugs that elicit an antiproliferative effect by
blocking intracellular protein recycling in transformed cells
represents a novel approach to the treatment of solid tumours
and haematological malignancies. The novel aminopeptidase
inhibitor tosedostat causes an AADR in malignant cells and also
inhibits angiogenesis; both effects may exert additional antitumour
activity when given in combination with chemotherapy.
The safety profile of oral daily dosing with tosedostat in a single
agent Phase I setting has been reported previously (Reid et al,
2009) and found to be good, with fatigue, thrombocytopenia,
peripheral oedema and diarrhoea as the most commonly reported
AEs; MTD with single agent tosedostat in solid tumour patients
treated for at least 28 days was 240mg. Dose-limiting toxicities
were reported in two of four patients treated at 320mg because of a
combination of thrombocytopenia, dizziness and visual abnorm-
alities in one patient, and anaemia, blurred vision and vomiting in
a second patient, leading to the patients being unable to complete
28 days of daily oral therapy.
This Phase 1b dose-escalation study was designed to investigate
the clinical safety, PK and preliminary antitumour activity of daily
oral tosedostat when administered with 3-weekly paclitaxel in
patients with advanced or metastatic cancer. Maximum tolerated
dose was not reached in this study. Apart from the infusion
reactions, combined tosedostat and paclitaxel therapy was
Table 3 Incidence of hypersensitivity reactions per dose level in cycle 2
Cohort
Patients with hypersensitivity
reaction/patients treated in cohort
1 2/3
2 0/4a
3 3/3
4 3/3
5 2/6
6 3/3
aIncluding Patient 4907 who was withdrawn after 7 days study treatment because
of early progressive disease.
Table 4 Effect of the coadministration of paclitaxel on the PK parameters (mean values (±s.e.m.)) of tosedostat (CHR-2797) and CHR-79888 (day 21
tosedostat without paclitaxel; day 22 tosedostat in combination with paclitaxel)
Cohort/doses Analyte Day Cmax (ngml1) Tmax (h) AUC0t (ng hml
1) T1
2
(h) Vz/F Cl/F
1. CHR-2797 90mg CHR-2797 21 522 (165) 1.2 (0.4) 1140 (401) 1.2 (0.1) 179 (67) 1771 (709)
Paclitaxel 135mgm2 22 289 (124) 4.0 (2.0) 896 (266) 2.4 (1.4) 258 (91) 1556 (514)
CHR-79888 21 544 (56) 4.7 (0.7) 6250 (311) 6.1 (0.2) 116 (9) 221 (11)
22 500 (108) 6.0 (1.2) 5550 (1680) 8.6 (ND) 103 (ND) 139 (ND)
2. CHR-2797 90mg CHR-2797 21 969 (367) 1.2 (0.4) 1890 (382) 1.3 (0.2) 72 (12) 654 (14)
Paclitaxel 175mgm2 22 527 (119) 2.0 (0) 1410 (315) 3.1 (1.0) 276 (84) 1160 (256)
CHR-79888 21 324 (40) 5.3 (0.7) 3510 (519) 5.6 (0.2) 204 (38) 417 (65)
22 364 (16) 4.7 (0.7) 4570 (438) 7.5 (1.0) 181 (7) 290 (37)
3. CHR-2797 130mg CHR-2797 21 880 (87) 1.7 (0.3) 1920 (328) 1.1 (0) 112 (22) 1204 (249)
Paclitaxel 175mgm2 22 615 (225) 1.3 (0.3) 1400 (457) 4.0 (2.7) 587 (296) 2011 (833)
CHR-79888 21 872 (37) 3.3 (0.7) 9440 (892) 5.9 (0.5) 108 (4) 217 (27)
22 723 (101) 5.3 (0.7) 9340 (1530) 7.1 (1.1) 142 (22) 242 (73)
4. CHR-2797 180mg CHR-2797 21 1400 (550) 1.7 (0.3) 2520 (730) 1.1 (0.1) 123 (26) 1352 (304)
Paclitaxel 175mgm2 22 399 (80) 4.0 (0) 1710 (99) 3.1 (0.3) 471 (70) 1758 (96)
CHR-79888 21 1270 (240) 4.0 (0) 9590 (1090) 4.6 (0) 113 (14) 283 (37)
22 1030 (188) 5.3 (0.7) 11600 (1620) 6.2 (0.3) 130 (19) 242 (30)
Abbreviations: AUC0t¼ area under the curve; Cl/F¼Apparent plasma clearance; Cmax¼maximum plasma concentration; ND¼ not determined; PK¼ pharmacokinetics;
Tmax¼ time of Cmax; t1
2
¼ biological half time; Vz/F¼ apparent volume of distribution.
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well tolerated, with only one DLT observed in 22 patients.
AEs were rarely more than moderate and were easily managed.
The incidence and severity of the main acute toxic effects of
neutropenia/leukopenia, anaemia, myalgia and nausea/vomiting
were not increased relative to paclitaxel alone.
A total of 13 patients (59%) experienced symptoms consistent with
an infusion reaction to paclitaxel, despite a routinely given
prophylactic regimen of dexamethasone plus histamine-1 and -2
receptor antagonists. One of the major limitations associated with the
use of paclitaxel and its Cremophor EL formulation concerns HSRs.
The mechanism of paclitaxel HSRs is not entirely known. Cremophor
EL is suspected to be the allergen (Weiss et al, 1990), but complement
and mast cell activation may be involved. Premedication regimens
and longer infusion times reduced reactivity to paclitaxel in the 1990s,
although in the presence of premedication this phenomenon
continues to occur in 10–34% of patients (Bristol Myers Squibb
(SPC), 2005). Although the HSRs can be medically managed, they can
be of considerable concern to patients (Markham et al, 2000).
Typically, around half of these reactions occur during the initial
infusion, but all HSRs in our combination trial were reported during
second and subsequent paclitaxel infusions. In an attempt to reduce
the possible stimulatory effect of tosedostat on paclitaxel-induced
HSRs, and taking into consideration the plasma t1
2
of CHR-79888
of 6–11h, it was decided to introduce a 5-day dosing window around
second and subsequent paclitaxel infusions in cohort 5. Although
this appeared to have a positive effect in patients on trial at that time
(two out of six patients experienced a HSR), all three patients in the
next cohort developed a HSR. Patients in cohorts 5 and 6 received
the same dose of paclitaxel (175mgm2), but the dose of tosedostat
was increased from 180 to 240mg. Even though paclitaxel-related
HSR was not included in the DLT definitions, the investigators
attributed the higher incidence of HSR to the combination of
tosedostat and paclitaxel; consequently, it was decided not to proceed
with a planned dose escalation of paclitaxel to 200mgm2. Because
tosedostat had also reached the MTD as determined in the single
agent Phase I study, further dose escalations were not indicated (Reid
et al, 2009). A formal explanation as to how tosedostat could enhance
HSR is lacking, but immunostimulatory activity has been described
with the use of the aminopeptidase inhibitor bestatin (Talmadge et al,
1986; Ichinose et al, 2003). It is probable that these infusion-related
reactions could be avoided by the use of a cremophor-free
formulation of paclitaxel (Gradishar, 2006).
In the patient who died during the study, a possible relationship
between this fatality and study drugs could not be excluded. We
attempted to identify the aetiology of the confirmed eosinophilic
myocarditis. Clearly, drugs scored high amongst the possible
candidates (Ginsberg and Parrillo, 2005), but in this patient there
was also a previous medical history of retrosternal pains, and his
pretreatment ECG revealed signs of cardiomegaly.
Tosedostat has been associated with a platelet suppressive effect
in the single agent dose escalation studies (Ossenkoppele et al,
2009; Reid et al, 2009). Although this did not require dose
interruption in patients treated with tosedostat monotherapy, this
may have been responsible for the delayed recovery after every
paclitaxel infusion in this combination study. Otherwise, the
cyclical pattern observed for the haematology parameters, with a
drop in values after each paclitaxel infusion that reached a nadir
on day 8 or day 15 of each cycle and recovered to baseline or just
below baseline on day 21, suggests that the observed phenomenon
was paclitaxel-related, although an additive effect of tosedostat
cannot be ruled out.
When tosedostat was coadministered with paclitaxel, the
exposure to tosedostat, as measured by the AUC0t, seemed to
have been unaffected by paclitaxel coadministration, although the
shape of the tosedostat profile may have been affected in some
patients. There was no observable effect of coadministration of
paclitaxel on the PK of CHR-79888. When paclitaxel was
coadministered with tosedostat, the PK of paclitaxel seemed to
be unaffected.
Treatment successes in early phase studies with tosedostat
monotherapy included a PR and several patients with disease
stabilisation of at least 6 months’ duration in patients with
metastatic cancer, and a 31.4% response rate in patients with
relapsed/refractory AML (Ossenkoppele et al, 2009; Reid et al,
2009). In this combination study of 21 assessable patients with
relapsed, heavily pretreated solid tumours, 3 (14%) had a PR. It is
not possible to determine whether the responses seen in this study
were induced by paclitaxel alone or whether the addition of
tosedostat contributed to these effects; however, this response rate
seemed similar to taxane monotherapy.
In conclusion, except for the high incidence of paclitaxel-related
infusion reactions despite the use of routine prophylactic regimes,
the combination of tosedostat with paclitaxel was well tolerated.
As PK parameters of paclitaxel appeared very similar when given
alone or in the presence of tosedostat, increased exposure to
paclitaxel cannot be the explanation for this increased incidence.
Treatment with this combination and regimen was considered to
be essentially safe, however, further development of tosedostat
administered with cremophor-formulated paclitaxel cannot be
recommended. The antiproliferative, synergistic and potential
immuno-modulatory properties of tosedostat do, however, warrant
further exploration in studies with cremophor-free formulations of
paclitaxel and with other agents.
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